Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) announces that further to its news release dated September 29, 2022 (the “ Default Announcement ”), the Company’s principal regulator, the British Columbia Securities Commission (the “ BCSC ”) granted a management cease trade order (the “ MCTO ”) on September 29, 2022, under National Policy 12-203 Management Cease Trade Orders (“ NP 12-203... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) announces that the filing of its audited annual financial statements for the year ended May 31, 2022, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the “ Annual Financial Filings ”) were not filed by the required filing deadline of September 28, 2022 (the “ Filing Deadline ”). The... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce that previously shipped genetics have cleared Israeli customs and are being raised as mother stock. “The Israeli market will now have access to premium Canadian high THC genetics,” notes CEO Phil... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”), a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor, is pleased to announce it has facilitated its first shipment of cannabis strains to Israel. The agreement for genetics is directly between United Greeneries Ltd, a licensed Canadian producer of high calibre craft cannabis,... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce that it has signed a distribution agreement for Praesidio Health (Praesidio) products with Pure Integrative Pharmacy (PURE). “I am excited to announce our first executed distribution agreement in... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce the appointment of Super Bowl XXVI MVP and mental health advocate Mr. Mark Rypien to its advisory board. CEO Phil Floucault notes, “Mr. Rypien had a distinguished 13-year career in the NFL during... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement. The Company issued 4,679,600 units (the “ Units ”) at a price of $0.05 per Unit for aggregate gross proceeds of $233,980 (the “ Offering ”). Each Unit consists of one common share of the Company (a “ Share ”) and one common... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for its first formulations. Praesidio Health (https://www.praesidiohealth.com/) is a... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) is pleased to announce that further to its acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately. As Isracann moves from development to operations, and to better accommodate the integration of natural health medicine (“NHM”) research and... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) is pleased to announce that, further to the Company’s news releases dated February 23, 2022 and March 28, 2022, it has closed its acquisition of Praesidio Health Inc. (“ Praesidio ”). Pursuant to the definitive agreement dated March 24, 2022 with Praesidio and the shareholders of Praesidio (the “ Praesidio Shareholders ”), the Company... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “ Company ”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “ Agreement ”) dated March 24, 2022 with Praesidio Health Inc. (“ Praesidio ”). Pursuant to the Agreement, the Company will acquire all of the issued and outstanding shares in the capital of Praesidio... Read More

VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on researching and developing innovative health solutions in conjunction with its advanced stage activities aimed at becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to announce that on February 16, 2022,... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on researching and developing innovative health solutions in conjunction with its advanced stage activities aimed at becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to announce that it has entered into a binding LOI to acquire Praesidio Health Inc. of Canada... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to provide an update of recent activities and outlook for Q1 2022. The COVID-19 global pandemic continues to impact virtually all aspects of supply chain management, global trade, individual economies, and of... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to announce the appointment of Mr. Phil Floucault to the position of Chief Executive Officer effective immediately. The Isracann team recognized that as it transitions from its initial developmental stages into an... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to announce the appointment of Mr. Peleg Agayuf as overall Manager of Farm Operations at its Ein Hahoresh Farm and further provides a corporate review and update of its activities in Israel. Mr. Agayuf brings... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce it has been granted a Foreign Owners Cannabis License by the Israeli Minister of Health. This important event paves the way to conclude a number of outstanding key partnership and regulatory... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”), an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor, is extremely pleased by recent reports and trend data which offers great promise for the future of cannabis both in Israel and major western markets. Recent reports indicate a growing movement towards recreational cannabis... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce it has entered a non-binding Letter of Intent (LOI) outlining an importation sales agreement with a major Israeli medical cannabis company. The proposed relationship is with one of the leading cannabis... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to report on the prevalence of media reports and public optimism regarding the future of recreational Cannabis building momentum across Israel. As the world turned the page on 2020, reports of recommendations from... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer is pleased to announce its flagship Hefer Valley-based Ein Hahoresh Farm is in full readiness to commence growing and production activities. With the phase one 54,000 sq. ft. of greenhouse canopy fully constructed and extensive... Read More

Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) an Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce that the Company has determined to advance foreign importation of Cannabis into Israel in response to perceived opportunity. The Israeli market for medical cannabis continues to grow at a rapid pace.... Read More